{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:33:15Z","timestamp":1793835195673,"version":"4.6.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Protein Phosphatase Methylesterase 1 (PPME1) is a methylesterase specific to phosphatase 2A, a tumor suppressor, and plays a key role in tumor development. Its impact on pan-cancer diagnosis, prognosis, and immune regulation is still uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed PPME1 expression across multiple carcinomas using TCGA, GEO, and other datasets, focusing on its transcriptional profile, prognostic value, genetic and epigenetic alterations, and immunological role. To substantiate our findings, we evaluated PPME1 expression and protein levels in breast cancer tissues through RT-qPCR, Western blotting, and immunohistochemical techniques. The role of PPME1 in tumor progression was evaluated\n                      <jats:italic>in vitro<\/jats:italic>\n                      using CCK-8, colony formation, wound healing, and Matrigel transwell assays, and\n                      <jats:italic>in vivo<\/jats:italic>\n                      using xenograft tumor models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our pan-cancer analysis demonstrates that PPME1 is upregulated in the majority of tumors and exhibits heterogeneous expression across immune and molecular subtypes. Elevated levels of PPME1 constitute an independent risk factor in various cancers, including BLCA, BRCA, HNSC, KICH, LIHC, and UVM, and are associated with a poor prognosis. It has moderate to high diagnostic accuracy and can impact the tumor microenvironment by modifying genomic stability, affecting immunotherapy outcomes, and altering the immune response from anti-tumor to tumor-promoting. Functional enrichment analysis indicates PPME1\u2019s involvement in DNA damage and repair, pathway activation, substance metabolism, protein modification, and immune regulation. In breast cancer, PPME1 mRNA and protein levels are elevated in tumor tissues compared to adjacent normal tissue. Functional experiments revealed that suppression of PPME1 significantly inhibits the migration, invasion, and tumor growth of breast cancer cells, suggesting that PPME1 may serve as a potential therapeutic target for breast cancer progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, our data indicate that PPME1 acts as an oncogenic driver in multiple cancer types, promoting BRCA progression by enhancing pro-tumorigenic pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1770711","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:43:47Z","timestamp":1773125027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["The value of Protein Phosphatase Methylesterase 1 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to breast cancer verification"],"prefix":"10.3389","volume":"17","author":[{"given":"Yiyang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Thyroid and Breast Surgery Department of the People\u2019s Hospital of Bayingolin Mongol Autonomous Prefecture","place":["Korla, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilimulati","family":"Ismtula","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenming","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Center of Digestive and Vascular, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0377-7","article-title":"The microbiome, cancer, and cancer therapy","volume":"25","author":"Helmink","year":"2019","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2025.108834","article-title":"Understanding the regulatory landscape of protein phosphatase 2A (PP2A): Pharmacological modulators and potential therapeutics","volume":"269","author":"Neale","year":"2025","journal-title":"Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","article-title":"CIP2A inhibits PP2A in human Malignancies","volume":"130","author":"Junttila","year":"2007","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aam7893","article-title":"Ca(2+)-dependent demethylation of phosphatase PP2Ac promotes glucose deprivation-induced cell death independently of inhibiting glycolysis","volume":"11","author":"Lee","year":"2018","journal-title":"Sci Signal"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e24247","DOI":"10.1002\/jcla.24247","article-title":"Hsa_circ_0050102 regulates the pancreatic cancer development via miR-218-5p\/PPME1 axis","volume":"36","author":"Feng","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i15.1745","article-title":"DNAH17-AS1 promotes pancreatic carcinoma by increasing PPME1 expression via inhibition of miR-432-5p","volume":"26","author":"Xu","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/lio2.593","article-title":"Long non-coding RNA HOTAIR\/microRNA-761 sponge regulates PPME1 and further influences cell biological functions in thyroid carcinoma","volume":"6","author":"Guo","year":"2021","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13353","article-title":"PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers","volume":"17","author":"Aakula","year":"2023","journal-title":"Mol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: An update to the integrated cancer data analysis platform","volume":"25","author":"Chandrashekar","year":"2022","journal-title":"Neoplasia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3307","article-title":"The human protein atlas: A spatial map of the human proteome","volume":"27","author":"Thul","year":"2018","journal-title":"Protein Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: an integrated repository portal for tumor-immune system interactions","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinformatics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac558","article-title":"GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels","volume":"24","author":"Liu","year":"2023","journal-title":"Brief Bioinform"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1002\/imt2.238","article-title":"Sangerbox 2: Enhanced functionalities and update for a comprehensive clinical bioinformatics data analysis platform","volume":"3","author":"Chen","year":"2024","journal-title":"Imeta"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac959","article-title":"TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment","volume":"51","author":"Han","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf423","article-title":"GEPIA3: Enhanced drug sensitivity and interaction network analysis for cancer research","volume":"53","author":"Kang","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky939","article-title":"CancerSEA: a cancer single-cell state atlas","volume":"47","author":"Yuan","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41576-019-0171-x","article-title":"Context is everything: aneuploidy in cancer","volume":"21","author":"Ben-David","year":"2020","journal-title":"Nat Rev Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.541","article-title":"Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer","volume":"4","author":"Kaur","year":"2015","journal-title":"Cancer Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3303-3","article-title":"Gene signature of the post-Chernobyl papillary thyroid cancer","volume":"43","author":"Handkiewicz-Junak","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415647","article-title":"The pan-cancer multi-omics landscape of FOXO family relevant to clinical outcome and drug resistance","volume":"23","author":"Xie","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.27146","article-title":"Genetic amplification of PPME1 in gastric and lung cancer and its potential as a novel therapeutic target","volume":"15","author":"Li","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02023","article-title":"Predictive biomarkers of immune checkpoint inhibitors-related toxicities","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0171","article-title":"Combined microsatellite instability and elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) might be a more promising immune biomarker in colorectal cancer","volume":"24","author":"Chen","year":"2019","journal-title":"Oncologist"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13398","article-title":"Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling","volume":"17","author":"Teleanu","year":"2023","journal-title":"Mol Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2018.10.008","article-title":"MDSC; the most important cell you have never heard of","volume":"40","author":"Tesi","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00414","article-title":"Alteration of the antitumor immune response by cancer-associated fibroblasts","volume":"9","author":"Ziani","year":"2018","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e076065","DOI":"10.1136\/bmj-2023-076065","article-title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial","volume":"383","author":"Ma","year":"2023","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"key":"B40","doi-asserted-by":"publisher","first-page":"eadf1128","DOI":"10.1126\/scitranslmed.adf1128","article-title":"Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer","volume":"15","author":"Xu","year":"2023","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1770711\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:43:48Z","timestamp":1773125028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1770711\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2026.1770711"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1770711","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1770711"}}